BioMark Diagnostics to Present at 3rd Annual Congress of the International Society of Liquid Biopsy

biomark diagnostics 3rd annual congress of international society of liquid biopsy

Liquid Biopsy Company "BioMark Diagnostics" to Present at the 3rd Annual Congress of the International Society of Liquid Biopsy to be held October 22, 2021

Vancouver, British Columbia – ( October 18th, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that it will hold a virtual stand at the III annual Congress of the International Society of Liquid Biopsy to showcase its innovative technology to a key audience with compelling data from previous studies that demonstrates the ability of its assays to detect early-stage lung cancer at very high levels of sensitivity and specificity.

“BioMark is proud to participate in this premiere event that aims to address the principal advances in the world of the liquid biopsy. The conference to be held virtually on October 22, 2021, will present the best clinical practices related to liquid biopsy and the latest advanced on cellular and molecular diagnostic technologies. BioMark is a proud sponsor of the event and will have Dr. Wishart, Director at The Metabolomics Innovation Centre (TMIC) present on the role of metabolomics in liquid biopsy with highlights on our dynamic and clinically applicable early lung cancer liquid biopsy assay,” says Rashid Bux, CEO of BioMark.

“The company intends to expand its visibility and cultivate collaborations with key opinion leaders and institutions as it prepares for a large clinical study intended to validate clinical utility of its early lung cancer detection. This study is expected to start later this fall with pivotal results expected early in 2022 that could establish the foundation of our blood-based assay for lung cancer screening”, says Rashid Bux. 

More information about the congress is available at”.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment early for hard to detect and treat cancers using liquid biopsy. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors. 

Further information about BioMark is available under its profile on the SEDAR website and on the CSE website

For further information on BioMark, please Contact:

Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: [email protected]

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark.  Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved, or disapproved the content of this press release.
Share this post:
Share on facebook
Share on twitter
Share on linkedin
Share on email

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
FSE: 20B

Related articles ...

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.